Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib

• Glavni autori: Gian Paolo Bombeccari (Autor), Umberto Garagiola (Autor), Francesco Pallotti (Autor), Margherita Rossi (Autor), Massimo Porrini (Autor), Aldo Bruno Giannì (Autor), Francesco Spadari (Autor)
• Format: Knjiga
• Izdano: SpringerOpen, 2017-12-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

Abstract Background Imatinib mesylate is an inhibitor of the tyrosine kinase Bcr-Abl and a first-line treatment for Philadelphia chromosome-positive chronic myeloid leukaemia (CML). Dermatological side effects include superficial oedema, pustular eruption, lichenoid reactions, erythroderma, and skin...